Cargando…

Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress

Nivolumab, formulated in the medicine Opdivo(®) (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torrente-López, Anabel, Hermosilla, Jesús, Salmerón-García, Antonio, Cabeza, José, Navas, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025134/ https://www.ncbi.nlm.nih.gov/pubmed/35456527 http://dx.doi.org/10.3390/pharmaceutics14040692

Ejemplares similares

The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
por: Torrente-López, Anabel, et al.
Publicado: (2021)

Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
por: Navas, Natalia, et al.
Publicado: (2020)

Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation
por: Hermosilla, Jesús, et al.
Publicado: (2020)

Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab()
por: Martínez-Ortega, Antonio, et al.
Publicado: (2016)

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab
por: Parker, Matthew JS, et al.
Publicado: (2018)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
por: Hermosilla, Jesús, et al.
Publicado: (2023)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
por: Narumi, Yoshitsugu, et al.
Publicado: (2018)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
por: Lou, Beilei, et al.
Publicado: (2021)

Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
por: Roither, Bernhard, et al.
Publicado: (2020)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
por: Sanborn, Rachel E, et al.
Publicado: (2022)

Therapeutic monoclonal antibody for sporotrichosis
por: Almeida, Sandro R.
Publicado: (2012)

Therapeutic Applications of Monoclonal Antibodies
por: Berger, Mitchell, et al.
Publicado: (2002)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
por: Phakham, Tanapati, et al.
Publicado: (2022)

Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244
por: Horspool, Alexander M., et al.
Publicado: (2023)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
por: Haustrate, Aurélien, et al.
Publicado: (2019)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies
por: Metzger, Philipp, et al.
Publicado: (2018)

Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer
por: Wu, Lipei, et al.
Publicado: (2022)

Vogt-Koyanagi-Harada Disease-Like Uveitis during Nivolumab (Anti-PD-1 Antibody) Treatment for Metastatic Cutaneous Malignant Melanoma
por: Obata, Shumpei, et al.
Publicado: (2019)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

The pharmacology and therapeutic applications of monoclonal antibodies
por: Castelli, María Sofía, et al.
Publicado: (2019)

Comprehensive Identification of Tumor-associated Antigens via Isolation of Human Monoclonal Antibodies that may be Therapeutic
por: Kurosawa, Yoshikazu
Publicado: (2009)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8hj6jj1ivhl9kpmrlqqr9op5g3